Decreased Neprilysin Immunoreactivity in Alzheimer Disease, but Not in Pathological Aging
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Although evidence suggests that extensive cortical beta-amyloid (Abeta) deposition is essential in Alzheimer disease (AD), it is also detected in nondemented elderly individuals with pathologic aging (PA). Given evidence that neutral endopeptidase (NEP) or neprilysin, a key enzyme for clearance of Abeta, is decreased in AD, the goal of the present study was to determine if NEP was also decreased in PA. We measured NEP immunoreactivity in frontal cortex of 12 AD and six PA cases and compared this with 10 normal (N) elderly individuals. None had any significant other pathology, and they were similar with respect to age, sex, and postmortem delay. In addition, Abeta1-40 and Abeta1-42 were measured by enzyme-linked immunosorbent assay (ELISA), whereas tau, synaptophysin, and alpha-synuclein were measured on Western blots. The AD cases had more neuritic plaques, neurofibrillary tangles, higher Braak stage, and more tau immunoreactivity in frontal cortex than both PA and N. In contrast, both PA and AD had more senile plaques and Abeta1-42 than N. NEP immunoreactivity was decreased in AD but not in PA. The decrease was unlikely the result of neuronal or synaptic loss because NEP immunoreactivity in frontotemporal degeneration with comparable degrees of synaptic loss as the AD cases was not different from control subjects. Although NEP enzyme activity was decreased in approximately half the AD cases, on average, it was not decreased compared with N or PA. The results add further evidence that PA is distinct from AD and indicate that decreased Abeta degradation by NEP is unlikely to contribute significantly to amyloid deposition in PA or, in many cases, of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799 · cited 11×
“There was no significant difference in Ab1-42 levels between AD and PA (Fig.”
BackgroundInfluentialThe Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Self-citationElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729 · cited 1×
“Several studies have detected an increase in BACE1 protein and enzyme activity in AD (13, 14), which implies that AD may be associated with increased production of Ab.”
BackgroundAmyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Self-citationNeuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674
Self-citationIdentification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643 · cited 7×
“Individuals with PA are clinically indistinguishable from those with no cortical Ab deposits even with prospective, longitudinal evaluations and sensitive neuropsychologic tests (4).”
BackgroundMethodResultInfluentialSelf-citationWang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567 · cited 3×
“A previous study found similar increases in Ab1-40 in AD compared with PA (5).”
BackgroundResultSelf-citationCorrelations of synaptic and pathological markers with cognition of the elderly
Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., & Davies, P. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00013-5 · Cited by 410 · cited 2×
“Moreover, quantitative studies have shown that, on average, there is as much Ab in PA as in AD (5, 6).”
BackgroundMethodSelf-citation“Preclinical” AD revisited: Neuropathology of cognitively normal older adults
Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000) · Neurology · doi:10.1212/wnl.55.3.370 · Cited by 369 · cited 1×
“Several other recent studies of prospectively studied elderly subjects have also described high amyloid burden in some clinically normal individuals (39, 40).”
Result
Cited by
Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 381
Elevation of glutathione as a therapeutic strategy in Alzheimer disease
Pocernich, C. B., & Butterfield, D. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.003 · Cited by 346
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
“Furthermore, the reduction in both NEP and IDE in AD was more pronounced in brain tissue from APOE ?4-positive patients (80, 106, 166, 167), whereas Hellstrom-Lindahl et al (168) reported decreased NEP protein (measured by immunoblot analysis) in AD and with age.”
Backgroundβ‐Amyloid Degradation and Alzheimer′s Disease
Wang, D.-S., Dickson, D. W., & Malter, J. S. (2006) · BioMed Research International · doi:10.1155/jbb/2006/58406 · Cited by 185
“These data support the hypothesis that decreased NEP contributes to Aβ deposition in AD, but perhaps in means that are not entirely linked to visible amyloid deposition [72], perhaps implicating failed degradation of toxic soluble intermediates in AD.”
BackgroundSelf-citationHarnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins
Chadarevian, J. P., Davtyan, H., Chadarevian, A. L., Nguyen, J., Capocchi, J. K., Le, L., Escobar, A., Chadarevian, T., Mansour, K., Deynega, E., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.009 · Cited by 60
Metadata
- Authors
- Wang, D.-S., Lipton, R. B., Katz, M. J., Davies, P., Buschke, H., Kuslansky, G., Verghese, J., Younkin, S. G., Eckman, C., & Dickson, D. W.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05
- Volume
- 64
- Issue
- 5
- Pages
- 378-385
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2303492114
- Cited by
- 85
- References
- 16
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decreased Neprilysin Immunoreactivity in Alzheimer Disease, but Not in Pathological Aging. https://app.cochat.ai/papers/10.1093/jnen/64.5.378
- The paper
- Wang, D.-S., Lipton, R. B., Katz, M. J., Davies, P., Buschke, H., Kuslansky, G., Verghese, J., Younkin, S. G., Eckman, C., & Dickson, D. W. (2005). Decreased Neprilysin Immunoreactivity in Alzheimer Disease, but Not in Pathological Aging. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/64.5.378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.